INVESTOR ALERT Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Helius Medical Technologies, Inc.
The law firm of Kirby McInerney LLP is investigating potential claims against Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ: HSDT). This investigation concerns whether Helius has violated federal securities laws and/or engaged in other unlawful business practices.
On April 10, 2019, Helius announced that the U.S. Food and Drug Administration (“FDA”) had declined the Company’s request for De Novo classification and 510(k) clearance of the Company’s Portable Neuromodulation Stimulator (PoNS) device.
On this news, shares of Helius fell $4.11, approximately 66.2%, to close at $2.10 on April 10, 2019.
If you acquired Helius securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at firstname.lastname@example.org, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.